IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended) A <u>tablet</u> composition for rapid disintegrating tablets in an oral cavity which comprises:

- (a) saccharides comprised of a combination of mannitol and one or more of other saccharide(s) selected from sorbitol, erythritol, maltitol, lactose, sucrose, glucose, fructose, maltose, trehalose, paratinit and paratinose are 40 to 90 parts by weight;
 - (b) an inorganic excipient is 1 to 30 part(s) by weight; and
 - (c) a disintegrating agent is 5 to 40 parts by weight, wherein a total amount of components (a), (b) and (c) is 100 parts by weight, [[and]] wherein a weight ratio of mannitol to other saccharide(s) is (98 to 75): (2 to 25), wherein the tablet composition exhibits an oral disintegration time of within 40 seconds.

Claim 2 (Original) The composition according to claim 1, wherein:

- (a) saccharides are 50 to 80 parts by weight;
- (b) the inorganic excipient is 2 to 15 parts by weight; and
- (c) the disintegrating agent is 10 to 35 parts by weight.

Claim 3 (Original) The composition according to claim 1, wherein:

- (a) saccharides are 65 to 80 parts by weight;
- (b) the inorganic excipient is 3 to 10 parts by weight; and
- (c) the disintegrating agent is 17 to 34 parts by weight.

Claim 4 (Previously Presented) The composition according to claim 1, wherein mannitol and other saccharide(s) form complex particles and the inorganic excipient and the disintegrating agent are dispersed in the complex particles.

Claim 5 (Original) The composition according to claim 4, wherein the complex particles form a solid dispersion.

Claim 6 (Cancelled).

Claim 7 (Previously Presented) The composition according to claim 1, wherein an endothermic peak of the saccharides is shifted to a low temperature side by 0.5 to 10°C compared to an endothermic peak measured from mannitol only.

Claim 8 (Previously Presented) The composition according to claim 1, wherein the ratio by weight of mannitol to other saccharide(s) is (97 to 75): (3 to 25).

Claim 9 (Previously Presented) The composition according to claim 1, wherein the ratio by weight of mannitol to other saccharide(s) is (96 to 81): (4 to 19).

Claim 10 (Previously Presented) The composition according to claim 1, wherein the inorganic excipient has an average pore diameter of 100 nm or less and is a pharmaceutically acceptable inorganic compound containing any of aluminum, magnesium and calcium.

Claim 11 (Previously Presented) The composition according to claim 1, wherein the inorganic excipient is selected from magnesium aluminometasilicate, magnesium aluminosilicate, synthetic hydrotalcite, calcium silicate, calcium hydrogen phosphate, calcium carbonate, talc and dry aluminum oxide gel.

Claim 12 (Previously Presented) The composition according to claim 1, wherein the disintegrating agent has an average particle diameter of 60 μ m or less, and is selected from crospovidone, low-substituted hydroxypropyl cellulose, crystalline cellulose and croscarmellose sodium.

Claim 13 (Original) The composition according to claim 12, wherein one or more of disintegrating agent having an average particle diameter of 20 μ m or less is contained.

Claim 14 (Withdrawn) The composition according to claim 1; wherein the disintegrating agent is crospovidone having an average particle diameter of 20 μ m or less and crystalline cellulose having an average particle diameter of 40 μ m or less.

Claim 15 (Withdrawn) The composition according to claim 1, which contains 5 to 13 parts by weight of crospovidone and 12 to 21 parts by weight of crystalline cellulose as the disintegrating agent.

Claim 16 (Previously Presented) The composition according to claim 1, which is obtained by spray-drying an aqueous solution or an aqueous dispersion comprising the saccharides, the disintegrating agent and the inorganic excipient.

Claim 17 (Original) The composition according to claim 16, which is obtained by spray-drying the dispersion obtained by dissolving or dispersing, in advance, mannitol and other saccharide(s) in an aqueous medium and then homogeneously dispersing the disintegrating agent and the inorganic excipient.

Claim 18 (Previously Presented) The composition according to claim 1, which further contains 0.01 to 100 parts by weight of a pharmacologically active ingredient and/or 0.01 to 1000 parts by weight of a component which does not deteriorate a disintegrating property based on 100 parts by weight of a total amount of the saccharides, the inorganic excipient and the disintegrating agent.

Claim 19 (Previously Presented) A rapid disintegrating tablet in oral cavity prepared by using the composition according to claim 1, which comprises 0.01 to 100 parts by weight of a pharmacologically active ingredient and/or 0.01 to 1000 parts by weight of a component which does not deteriorate a disintegrating property based on 100 parts by weight of the composition.

Claim 20 (New) The tablet composition according to claim 1, wherein the tablet composition exhibits an oral disintegration time of within 30 seconds.

Claim 21 (New) The tablet composition according to claim 1, wherein the tablet composition exhibits an oral disintegration time of within 20 seconds.